Atrium Therapeutics, Inc. (RNA)
NASDAQ · Manufacturing · Pharmaceutical preparations
$8.12−$0.0700 (−0.85%) on the dayAs of the close; data may be delayed.
RNA price, last 12 months
Key stats
- Previous close
- $8.19
- Open
- $8.20
- Day range
- $8.10 – $8.37
- 52-week range
- $8.10 – $73.06
- Volume
- 190.8K
- Avg volume (20 days)
- 405.4K
- Market cap
- $141.8M
Performance
1W−9.3%
1M−41.4%
3M−38.4%
6M−38.0%
YTD−88.7%
1Y−80.8%
vs S&P 500, 1Y−97.6 pts
Technicals and fundamentals
About Atrium Therapeutics, Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $141.8M